TScan Therapeutics Inc expected to post a loss of 21 cents a share - Earnings Preview

Tscan Therapeutics

07/08/2026 16:38

TScan Therapeutics Inc TCRX.OQ TCRX.O is expected to  show a fall in quarterly revenue when it reports  results on August 10 (estimated) for the period ending June 30 2026
The Waltham Massachusetts-based  company is expected to report a 45.8% decrease in revenue to $1.667 million from $3.08 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
​LSEG's mean analyst estimate for TScan Therapeutics Inc is for a loss of 21 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for TScan Therapeutics Inc is $6.00, about 686.2% above its last closing price of $0.76
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.17
-0.17
-0.22
Missed
-27.9
Dec. 31 2026
-0.23
-0.24
-0.18
Beat
25.4
Sep. 30 2025
-0.29
-0.30
-0.28
Beat
5.2​
Jun. 30 2025
-0.28
-0.28
-0.28
Met
0.2
​​Mar. 31 2025
-0.29
-0.29
-0.26
Beat
9.1
Dec. 31 2024
-0.27
-0.27
-0.30
Missed
-9.6​
Sep. 30 2024
-0.29
-0.29
-0.25
Beat
13.1
Jun. 30 2024
-0.28
-0.28
-0.28
Met
1
This summary was machine generated August 7 at 15:38 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)